134 related articles for article (PubMed ID: 38458479)
1. Long-Term Clinical Outcomes and B Cell Immune Reconstitution Following Allo-HCT With Prophylactic, Post-Transplant Rituximab.
Kennedy VE; Sahaf B; Wu F; Ehlinger ZJ; Arai S; Miklos DB
Transplant Cell Ther; 2024 May; 30(5):518.e1-518.e13. PubMed ID: 38458479
[TBL] [Abstract][Full Text] [Related]
2. Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia.
Llaurador G; Shaver K; Wu M; Wang T; Gillispie A; Doherty E; Craddock J; Read J; Yassine K; Morales E; George A; Steffin D; Krance R; Martinez C; Heslop H; Salem B
Transplant Cell Ther; 2024 Feb; 30(2):217-227. PubMed ID: 37931800
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
5. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
6. Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
Kołodziejczak M; Gil L; de la Camara R; Styczyński J;
Ann Hematol; 2021 Mar; 100(3):763-777. PubMed ID: 33491135
[TBL] [Abstract][Full Text] [Related]
7. Increased Infections and Delayed CD4
Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
[TBL] [Abstract][Full Text] [Related]
8. Impact of low-dose anti-thymocyte globulin on immune reconstitution after allogeneic hematopoietic cell transplantation.
Ito A; Kitano S; Tajima K; Kim Y; Tanaka T; Inamoto Y; Kim SW; Yamamoto N; Fukuda T; Okamoto S
Int J Hematol; 2020 Jan; 111(1):120-130. PubMed ID: 31641956
[TBL] [Abstract][Full Text] [Related]
9. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
10. Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Maturation Block of IgM Memory B Cells May Lead to Impaired Antibody Immune Reconstitution.
Abdel-Azim H; Elshoury A; Mahadeo KM; Parkman R; Kapoor N
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1437-1446. PubMed ID: 28495643
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.
Nakasone H; Sahaf B; Miklos DB
Int J Hematol; 2015 May; 101(5):438-51. PubMed ID: 25812839
[TBL] [Abstract][Full Text] [Related]
12. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
[TBL] [Abstract][Full Text] [Related]
13. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.
Lin C; DiCioccio RA; Haykal T; McManigle WC; Li Z; Anand SM; Poe JC; Bracken SJ; Jia W; Alyea EP; Cardones AR; Choi T; Gasparetto C; Grunwald MR; Hennig T; Kang Y; Long GD; Lopez R; Martin M; Minor KK; Quinones VLP; Sung AD; Wiggins K; Chao NJ; Horwitz ME; Rizzieri DA; Sarantopoulos S
Transplant Cell Ther; 2023 Mar; 29(3):179.e1-179.e10. PubMed ID: 36577483
[TBL] [Abstract][Full Text] [Related]
14. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
15. Immune Status Against Hepatitis B in Patients After Allogeneic Hematopoietic Cell Transplantation-Factors Affecting Early and Long-Lasting Maintenance of Protective Anti-HBs Titers.
Piekarska A; Wisniewski P; Lewandowski K; Gil L; Trzonkowski P; Bieniaszewska M; Zaucha JM
Front Immunol; 2020; 11():586523. PubMed ID: 33335530
[TBL] [Abstract][Full Text] [Related]
16. Outcome of autoimmune cytopenia after hematopoietic cell transplantation in primary immunodeficiency.
Lum SH; Selvarajah S; Deya-Martinez A; McNaughton P; Sobh A; Waugh S; Burton-Fanning S; Newton L; Gandy J; Nademi Z; Owens S; Williams E; Emonts M; Flood T; Cant A; Abinun M; Hambleton S; Gennery AR; Slatter M
J Allergy Clin Immunol; 2020 Aug; 146(2):406-416. PubMed ID: 32442647
[TBL] [Abstract][Full Text] [Related]
17. Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial.
Gooptu M; Kim HT; Chen YB; Rybka W; Artz A; Boyer M; Johnston L; McGuirk J; Shea TC; Jagasia M; Shaughnessy PJ; Reynolds CG; Fields M; Alyea EP; Ho VT; Glavin F; Dipersio JF; Westervelt P; Ritz J; Soiffer RJ
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2216-2223. PubMed ID: 30006305
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.
Arai S; Sahaf B; Narasimhan B; Chen GL; Jones CD; Lowsky R; Shizuru JA; Johnston LJ; Laport GG; Weng WK; Benjamin JE; Schaenman J; Brown J; Ramirez J; Zehnder JL; Negrin RS; Miklos DB
Blood; 2012 Jun; 119(25):6145-54. PubMed ID: 22563089
[TBL] [Abstract][Full Text] [Related]
19. Immune Reconstitution Following TCRαβ/CD19-Depleted Hematopoietic Cell Transplantation for Hematologic Malignancy in Pediatric Patients.
Arnold DE; MacMath D; Seif AE; Heimall JR; Wang Y; Monos D; Grupp SA; Bunin NJ
Transplant Cell Ther; 2021 Feb; 27(2):169.e1-169.e9. PubMed ID: 33830028
[TBL] [Abstract][Full Text] [Related]
20. Immune reconstitution and survival of patients after allogeneic hematopoietic stem cell transplantation from older donors.
Jiang P; Cai Y; Zhou X; Yang J; Tong Y; Huang C; Qiu H; Zhou K; Xu X; Zhang Y; Niu J; Shen C; Xia X; Wei Y; Song X; Wan L
Clin Transplant; 2023 Jan; 37(1):e14844. PubMed ID: 36318732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
